Japanese Mushroom Boosts Colon Cancer Survival 53%

It’s a powerful mushroom extract that’s proven to save colon cancer patients’ lives…

And the American medical establishment has ignored it for 49 years.

It’s hard to believe… but it’s true.

From the moment you’re diagnosed with colon cancer, American mainstream medicine only gives you two options.

They’ll cut it out with painful surgery… or poison it out with toxic chemotherapy.

And if neither of those work… well, you’re stuck.

But for the past 49 years, Japan has done things differently.

They’ve added a cancer-hunting compound from a simple mushroom to their colon cancer treatment program.

And it’s now been shown to extend even the most vulnerable cancer patients’ lives by up to 53%.

So why haven’t you been told anything about it?

The compound is PSK—also called Krestin—extracted from the turkey tail mushroom.

Traditional Chinese and Japanese healers used turkey tail for centuries to strengthen vitality and support the immune system. But in the 1960s, Japanese researchers isolated its most active component: protein-bound polysaccharide-K (PSK), which activates immune cells to hunt cancer.

By 1977, PSK became an approved add-on to cancer therapy in Japan. Today, it’s covered by national health insurance and routinely prescribed alongside chemotherapy for colorectal, gastric, and lung cancers.

And the clinical data backing it up is remarkable…

Japanese researchers conducted a meta-analysis of three studies involving 1,094 colorectal cancer patients who’d undergone surgery and received standard chemotherapy.

Half were also given PSK. Half received chemo alone.

The PSK group showed a 29% reduction in death risk – and they were 28% less likely to see their cancer come back.

The survival benefit held up across follow-up periods ranging from five to ten years.

But the most striking results came from elderly patients, who are most at risk of dying from colon cancer.

In patients over 70—often considered too fragile for aggressive treatment—three-year survival with PSK reached 80.8%. Without PSK? Just 52.8%.

That’s a whopping 53% improvement… using nothing more complicated than a mushroom compound.

So how does PSK accomplish what chemotherapy alone can’t?

It activates your immune system to keep hunting residual cancer cells long after treatment ends.

Chemotherapy kills cancer cells directly. But it’s a blunt weapon—it can’t distinguish between rapidly dividing cancer cells and rapidly dividing immune cells. It often damages the very immune system needed to prevent cancer from coming back.

PSK works differently. Its beta-glucans bind to receptors on immune cells—natural killer cells, T-cells, macrophages—and activate them. It essentially trains your immune system to recognize and destroy cancer cells that surgery and chemo might have missed.

Japan figured this out 50 years ago. PSK has been prescribed to millions of cancer patients there since the 1970s. It’s backed by decades of clinical trials, real-world use, and safety data.

It’s still completely ignored in American cancer care… but that doesn’t mean you can’t explore it.

Turkey tail mushroom extracts are widely available as supplements in the U.S., though they’re not standardized to the same PSK formulation used in Japanese trials.

Look for extracts standardized to at least 30% polysaccharides or specifically labeled as containing PSP or PSK.

The doses used in Japanese studies were typically 3 grams daily, divided into three doses with meals, continued for years after completing chemotherapy.

Anyone considering this should discuss it with their oncology team. PSK has an excellent safety profile, but coordination with your existing treatment is essential.

Colon cancer doesn’t have to be a waiting game—hoping the surgery worked, hoping the chemo got everything, hoping it doesn’t come back.

Maybe it’s time to stop hoping… and give your body the tools to start hunting.

To giving your immune system the support it was meant to have,

Rachel Mace
Managing Editorial Director, e-Alert
with contributions from the research team

Sources:

• Sakamoto J, Morita S, Oba K, et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled trials. Cancer Immunology, Immunotherapy. 2006;55(4):404-411. https://pubmed.ncbi.nlm.nih.gov/16389486/
• National Cancer Institute. Medicinal Mushrooms (PDQ®)–Health Professional Version. Updated 2024. https://www.cancer.gov/about-cancer/treatment/cam/hp/mushrooms-pdq